ArticleScientific reports2026
Molecular recognition and induced dimerization of hnRNP A2/B1 truncations by G-quadruplex single strand DNA.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Proteomic screening identifies HNRNPA2B1 as an epigenetic repressor of Epstein-Barr virus reactivation.Journal of virology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Heterogeneous nuclear ribonucleoprotein A2/B1 (hnRNP A2/B1) is a multifunctional nucleic acid metabolism regulator with established roles in viral infection and tumorigenesis. However, a critical gap exists between the oligomeric state of hnRNP A2/B1 and its function as a nuclear DNA sensor. To address this gap, we generated full-length hnRNP A2/B1 and three domain-truncated variants (△NLS, RRM-PrLD, RRM-RGG) using SUMO/MBP fusion expression systems. To define the nucleic acid binding and oligomeric properties of these variants, we combined SEC with EMSA and ITC. These analyses revealed that full-length hnRNP A2/B1 forms soluble amorphous aggregates, whereas the truncated variants exist as stable homogeneous monomers under in vitro solution conditions. Additionally, results demonstrated that the RRM-RGG (15-250) variant binds to ssDNA but not dsDNA. Notably, SEC combined with CD and AUC confirmed that RRM-RGG (15-250) truncations undergo homodimerization induced by 12nt and 22nt Guanine quadruplex (G4) structure enriched ssDNA, which is abundant in the genomes of diverse viruses. Structure predictions revealed that the C-terminal PrLD, and NLS domain are intrinsically disordered, a feature potentially underlying the protein's aggregation propensity and crystallization recalcitrance. NPDock simulations demonstrated that G4-structured ssDNA binds and stabilizes the RRM-RGG (15-250) truncation via non-conserved key residues that are distinct from those of other hnRNP family members. This work provides a biophysical basis for hypothesizing that G4-structured ssDNA-dependent dimerization may contribute to the protein's antiviral function, and establishes a biophysical framework to guide future investigations into the protein's antiviral mechanism and the design of rational targeted inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.